Neoplasms

Inclusion Criteria

- Subjects with histologically confirmed, locally advanced or metastatic, refractory solid tumors who are not candidates for standard therapy
 - Male or female subject ≥ 18 years of age
 - Women of childbearing potential must have a negative urine pregnancy test performed within 7 days before start of study treatment
 - Life expectancy at least 8 weeks
 - Adequate bone marrow, and liver function as assessed by the following laboratory requirements conducted within 7 days of starting the study treatment
 - Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2
 - For subjects with NORMAL OR MILDLY IMPAIRED RENAL FUNCTION (Control group); to be tested within 7 days of starting the study treatment:
 -- Estimated creatinine clearance (CLcr) ≥ 60 mL/min as calculated using the Cockcroft-Gault equation 
 - For subjects with SEVERELY IMPAIRED renal function; to be tested within 7 days of starting the study treatment:
 -- CLcr 15-29 mL/min as calculated using the Cockcroft-Gault equation

Exclusion Criteria

- Symptomatic metastatic brain or meningeal tumors
 - Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication
 - History of organ allograft
 - Non-healing wound, skin ulcer, or bone fracture
 - Pheochromocytoma
 - Uncontrolled concurrent medical illness including uncontrolled hypertension
 - History of cardiac disease
 - Pleural effusion or ascites that causes respiratory compromise
 - Interstitial lung disease with ongoing signs and symptoms at the time of screening
 - Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months before the start of study medication
 - Subjects with evidence or history of bleeding diathesis; any hemorrhage or bleeding event NCI-CTCAE Grade ≥ 3 or higher within 4 weeks of start of investigational treatment
 - Dehydration NCI-CTCAEversion 4.0 Grade ≥ 1
 - Unresolved toxicity higher than NCI-CTCAE version 4.0 Grade 1 attributed to any prior therapy/procedure (excluding alopecia or anemia or grade 2 neuropathy that is not reversible due to oxaliplatin)
 - Seizure disorder requiring anticonvulsant therapy (such as steroids or anti-epileptics)
 - For subjects with SEVERELY IMPAIRED renal function:
 -- Renal failure requiring hemo- or peritoneal dialysis
 -- Acute renal failure
 -- Acute nephritis
 -- Nephrotic syndrome